Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-649-3 | CAS number: 33704-61-9
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study is done according to OECD TG 421 under GLP
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD TG 421
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one
- EC Number:
- 251-649-3
- EC Name:
- 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4H-inden-4-one
- Cas Number:
- 33704-61-9
- Molecular formula:
- C14H22O
- IUPAC Name:
- 1,1,2,3,3-pentamethyl-1,2,3,5,6,7-hexahydro-4H-inden-4-one
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- See 7.8.1
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- see IUCLID 7.8.1
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- see IUCLID 7.8.1
- Details on mating procedure:
- see IUCLID 7.8.1
- Duration of treatment / exposure:
- see IUCLID 7.8.1
- Frequency of treatment:
- see IUCLID 7.8.1
- Duration of test:
- see IUCLID 7.8.1
Doses / concentrations
- Remarks:
- Doses / Concentrations:
see IUCLID 7.8.1
Basis:
Results and discussion
Results: maternal animals
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- >= 120 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Cashmeran is not a developmental toxic substance. No effects were seen at 120 mg/kg bw
- Executive summary:
A reproscreening study in accordance with OECD 421 was performed to determine the reprotoxic/developmental toxic potential of Cashmeran. Cashmeran was given orally in the diet to Wistar rats at 0, 150, 600 or 1875 mg Cashmeran/kg food during a premating period of 2 weeks and during mating (1 week), gestation and lactation until postnatal day 4. The homogeneity, stability and content of the test substance in the diets were confirmed by analysis.
No treatment-related changes in appearance, general condition or behaviour of the animals were observed. Mean body weight and body weight change were slightly decreased in the high dose group of the male animals. Also, food consumption was slightly decreased in this dose group, in both male and female animals. The effects on body weight could only partly be explained by the decrease in food consumption, therefore, this effect was considered to be treatment-related.
Increased organ weights (kidney and liver) were observed in male rats at the mid- and high-dose. At the low dose level also an increase was observed, however, this increase was considered to be minimal. No treatment-related effects on organ weight were observed in females. Histopathologically, an increased incidence of basophilic tubules was observed at the low-, mid- and high-dose. In the low- and mid-dose this increase was considered not toxicologically relevant due to the high incidence in the control and absence of increase in severity. Specific assessment of alpha-2u-microglobulins did not demonstrate treatment-related differences. Therefore it was concluded that no histopathological changes were observed that could explain the increased kidney weights in the treated animals.
No treatment related effects were observed in reproduction indices, except for a statistically significant increase in pre-implantion loss in the highest dose group. However, as this effect was mainly due to 2 females in this group and the mean pre-implantation loss was within the historical control range, this effect was considered to be not related to treatment. No treatment-related effects on pups were observed.
Based on the results, the NOAELparental is considered to be 150 mg/kg food, corresponding to an overall intake of 9.76 mg/kg bw/d for males. No effects were observed on fertility and the development. Therefore, the NOAELfertility/developmental toxicity is 1875 mg/kg food, corresponding to 115.24 mg/kg bw/d for males and 121.83 mg/kg bw/d for females. Based on these results, Cashmeran is considered to be not reprotoxic/toxic for the development.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
